BR9607951A - Derivados de mercapto e seleno como inibidores de sintase de óxido nítrico - Google Patents

Derivados de mercapto e seleno como inibidores de sintase de óxido nítrico

Info

Publication number
BR9607951A
BR9607951A BR9607951A BR9607951A BR9607951A BR 9607951 A BR9607951 A BR 9607951A BR 9607951 A BR9607951 A BR 9607951A BR 9607951 A BR9607951 A BR 9607951A BR 9607951 A BR9607951 A BR 9607951A
Authority
BR
Brazil
Prior art keywords
nitric oxide
oxide synthase
mercapto
selene
derivatives
Prior art date
Application number
BR9607951A
Other languages
English (en)
Inventor
Garry J Southan
Andrew L Salzman
Csaba Szabo
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/410,312 external-priority patent/US5674907A/en
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BR9607951A publication Critical patent/BR9607951A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9607951A 1995-03-24 1996-03-22 Derivados de mercapto e seleno como inibidores de sintase de óxido nítrico BR9607951A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/410,312 US5674907A (en) 1995-03-24 1995-03-24 Mercapto derivatives as inhibitors of nitric oxide synthase
US08/545,952 US5929063A (en) 1995-03-24 1995-10-20 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
PCT/US1996/003838 WO1996030007A1 (en) 1995-03-24 1996-03-22 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase

Publications (1)

Publication Number Publication Date
BR9607951A true BR9607951A (pt) 1999-06-01

Family

ID=27020952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607951A BR9607951A (pt) 1995-03-24 1996-03-22 Derivados de mercapto e seleno como inibidores de sintase de óxido nítrico

Country Status (17)

Country Link
US (2) US5929063A (pt)
EP (1) EP0814792B1 (pt)
JP (1) JPH11502847A (pt)
CN (1) CN1275594C (pt)
AT (1) ATE241347T1 (pt)
AU (1) AU695307B2 (pt)
BR (1) BR9607951A (pt)
CA (1) CA2214601C (pt)
CZ (1) CZ293497A3 (pt)
DE (1) DE69628416T2 (pt)
DK (1) DK0814792T3 (pt)
HU (1) HUP9801698A3 (pt)
MX (1) MX9707278A (pt)
NZ (1) NZ305228A (pt)
RU (1) RU2191575C2 (pt)
TR (1) TR199701013T1 (pt)
WO (1) WO1996030007A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1212620A (zh) * 1996-03-05 1999-03-31 儿童医院医疗中心 作为环氧酶抑制剂的巯基衍生物
AU3128197A (en) * 1996-05-30 1998-01-05 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
JP2001507696A (ja) 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
FR2782642B1 (fr) 1998-08-31 2001-12-07 Xavier Forceville Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
BR9913526A (pt) 1998-09-08 2001-06-05 Monsanto Co Métodos de tratamento da osteoartrite com inibidores de sintase de óxido nìtrico induzìvel
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
WO2007022331A2 (en) * 2005-08-16 2007-02-22 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor
TW200744658A (en) * 2005-10-12 2007-12-16 Pentapharm Ag Topical composition for use as a skin lightener
WO2008128189A1 (en) 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods
US8003633B1 (en) 2008-04-14 2011-08-23 The Penn State Research Foundation Anti-cancer compositions and methods
CN114057619B (zh) * 2020-07-31 2024-03-22 深圳福山生物科技有限公司 有机硒化合物及其治疗用途
CN115785573B (zh) * 2022-12-02 2024-05-17 福建奥翔体育塑胶科技股份有限公司 一种持久抗菌型epdm颗粒及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400319A (en) * 1972-04-20 1975-07-16 Smith Kline French Lab Pharmaceutical compositions
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
ATE191847T1 (de) * 1991-12-16 2000-05-15 Univ Washington Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
EP0670720A1 (en) * 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzyme inhibitors

Also Published As

Publication number Publication date
CA2214601C (en) 2001-09-25
CA2214601A1 (en) 1996-10-03
ATE241347T1 (de) 2003-06-15
DK0814792T3 (da) 2003-09-29
RU2191575C2 (ru) 2002-10-27
HUP9801698A2 (hu) 1998-11-30
DE69628416T2 (de) 2004-05-06
HUP9801698A3 (en) 2000-07-28
AU5319196A (en) 1996-10-16
TR199701013T1 (xx) 1998-02-21
WO1996030007A1 (en) 1996-10-03
MX9707278A (es) 1998-06-30
CZ293497A3 (cs) 1998-02-18
US5985917A (en) 1999-11-16
DE69628416D1 (de) 2003-07-03
CN1275594C (zh) 2006-09-20
EP0814792B1 (en) 2003-05-28
CN1181700A (zh) 1998-05-13
NZ305228A (en) 1999-01-28
EP0814792A1 (en) 1998-01-07
AU695307B2 (en) 1998-08-13
US5929063A (en) 1999-07-27
JPH11502847A (ja) 1999-03-09

Similar Documents

Publication Publication Date Title
BR9607951A (pt) Derivados de mercapto e seleno como inibidores de sintase de óxido nítrico
UA49006C2 (uk) Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
HUP9900655A1 (hu) Eljárás a bőr fényöregedésének gátlására
NZ334512A (en) Method of using tetracycline compounds for inhibition of nitric oxide production
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
AU2001248701A1 (en) Inhibitors of histone deacetylase
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
BR9908869A (pt) Composição para evitar ou tratar distúrbios da pele
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
DK1233958T3 (da) Hæmmere af histondeacetylase
DK0758233T3 (da) PDE IV-inhibitorer til behandling af multipel sklerose
BR9811099A (pt) Inibidores de urocinase
ATE432923T1 (de) 5-aminoindenoä1,2-cüpyrazol-4-one als antitumor- und wachstumshemmende mittel
IL128691A0 (en) Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
PL328412A1 (en) Derivatives of benzamidine substituted with derivatives of amino acid and hydroxy acid as well as their application as antithrombotic agents
JO1696B1 (en) Acetamide derivatives
YU7901A (sh) Nova primena derivata taksoida
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
ES2136581A1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
AU1759901A (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
TR199801731T2 (xx) Siklooksijenaz önleyicileri olarak merkapto türevleri.
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36O DA LPI